Literature DB >> 15593001

Brain-derived neurotrophic factor protects against multiple forms of brain injury in bacterial meningitis.

Yoeng-Delphine Bifrare1, Jürg Kummer, Philipp Joss, Martin G Täuber, Stephen L Leib.   

Abstract

BACKGROUND: Brain-derived neurotrophic factor (BDNF) blocks activation of caspase-3, reduces translocation of apoptosis-inducing factor (AIF), attenuates excitotoxicity of glutamate, and increases antioxidant enzyme activities. The mechanisms of neuroprotection suggest that BDNF may be beneficial in bacterial meningitis.
METHODS: To assess a potentially beneficial effect of adjuvant treatment with BDNF in bacterial meningitis, 11-day-old infant rats with experimental meningitis due to Streptococcus pneumoniae or group B streptococci (GBS) were randomly assigned to receive intracisternal injections with either BDNF (3 mg/kg) or equal volumes (10 mu L) of saline. Twenty-two hours after infection, brains were analyzed, by histomorphometrical examination, for the extent of cortical and hippocampal neuronal injury.
RESULTS: Compared with treatment with saline, treatment with BDNF significantly reduced the extent of 3 distinct forms of brain cell injury in this disease model: cortical necrosis in meningitis due to GBS (median, 0.0% [range, 0.0%-33.7%] vs. 21.3% [range, 0.0%-55.3%]; P<.03), caspase-3-dependent cell death in meningitis due to S. pneumoniae (median score, 0.33 [range, 0.0-1.0] vs. 1.10 [0.10-1.56]; P<.05), and caspase-3-independent hippocampal cell death in meningitis due to GBS (median score, 0 [range, 0-2] vs. 0.88 [range, 0-3.25]; P<.02). The last form of injury was associated with nuclear translocation of AIF.
CONCLUSION: BDNF efficiently reduces multiple forms of neuronal injury in bacterial meningitis and may hold promise as adjunctive therapy for this disease.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15593001     DOI: 10.1086/426399

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  26 in total

1.  Use of corticosteroids and other adjunct therapies for acute bacterial meningitis in adults.

Authors:  Kameshwar Prasad; Nirendra Kumar Rai; Amit Kumar
Journal:  Curr Infect Dis Rep       Date:  2012-08       Impact factor: 3.725

2.  Adjunctive daptomycin attenuates brain damage and hearing loss more efficiently than rifampin in infant rat pneumococcal meningitis.

Authors:  Denis Grandgirard; Melchior Burri; Philipp Agyeman; Stephen L Leib
Journal:  Antimicrob Agents Chemother       Date:  2012-05-29       Impact factor: 5.191

3.  How to differentiate bacterial from viral meningitis.

Authors:  Werner Zimmerli
Journal:  Intensive Care Med       Date:  2005-10-22       Impact factor: 17.440

4.  Restoration of Akt activity by the bisperoxovanadium compound bpV(pic) attenuates hippocampal apoptosis in experimental neonatal pneumococcal meningitis.

Authors:  Matthias D Sury; Lorianne Vorlet-Fawer; Claudia Agarinis; Shida Yousefi; Denis Grandgirard; Stephen L Leib; Stephan Christen
Journal:  Neurobiol Dis       Date:  2010-09-25       Impact factor: 5.996

5.  Acute Bacterial Meningitis: Challenges to Better Antibiotic Therapy.

Authors:  Colin Kietzman; Elaine Tuomanen
Journal:  ACS Infect Dis       Date:  2019-07-03       Impact factor: 5.084

Review 6.  Pathogenesis and pathophysiology of pneumococcal meningitis.

Authors:  Barry B Mook-Kanamori; Madelijn Geldhoff; Tom van der Poll; Diederik van de Beek
Journal:  Clin Microbiol Rev       Date:  2011-07       Impact factor: 26.132

7.  Increase of BDNF serum concentration during donepezil treatment of patients with early Alzheimer's disease.

Authors:  T Leyhe; Elke Stransky; G W Eschweiler; G Buchkremer; C Laske
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2007-11-07       Impact factor: 5.270

Review 8.  Animal models of Streptococcus pneumoniae disease.

Authors:  Damiana Chiavolini; Gianni Pozzi; Susanna Ricci
Journal:  Clin Microbiol Rev       Date:  2008-10       Impact factor: 26.132

9.  Tracking the transcriptional host response from the acute to the regenerative phase of experimental pneumococcal meningitis.

Authors:  Matthias Wittwer; Denis Grandgirard; Janine Rohrbach; Stephen L Leib
Journal:  BMC Infect Dis       Date:  2010-06-17       Impact factor: 3.090

10.  Could proteomic research deliver the next generation of treatments for pneumococcal meningitis?

Authors:  U R Goonetilleke; S A Ward; S B Gordon
Journal:  Interdiscip Perspect Infect Dis       Date:  2009-05-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.